Journal article · 2024 · Open access

Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis

Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, Paraskevi Avgerou, George D. Kitas, Maria Tzitiridou‐Chatzopoulou, Theodoros Dimitroulas

Mediterranean Journal of Rheumatology, 35(Suppl 1), 10 · Published 1 March 2024 · DOI 10.31138/mjr.171023.rof

Open full textCite this paper

In brief

“Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis” is a 2024 journal article by Styliani Partalidou and 6 co-authors, published in Mediterranean Journal of Rheumatology. OpenAlex counts 19 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Mediterranean Journal of Rheumatology.

Citations
19
Most cited in
2026 (12)
References
46
Authors
7

Abstract

Objective: The aim of this study was to compare the risk of major cardiovascular events (MACE) and venous thromboembolic events (VTE) between tumour necrosis factor (TNF) and Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA). Methods: We researched PubMed, Scopus, Cochrane Library, and clinicaltrials.gov until December of 2023 for randomised controlled trials (RCTs) and observational studies. The outcomes studied were MACE (stroke, heart attack, myocardial infarction, sudden cardiac death) and VTE (deep vein thrombosis, pulmonary embolism). We pooled data using random effects model. Risk for the reported outcomes was expressed as odds ratio (OR) with a 95% confidential interval (CI). We performed a subgroup analysis based on study design. Results: We identified 23 studies, 20 of which compared the odds for MACE and 14 the odds for VTE between JAK and TNF inhibitors in RA patients. Ten studies were RCTs and the rest were observational. Regarding MACE risk we pooled data from a total of 215,278 patients (52,243 were treated with JAK inhibitors, while the rest 163,035 were under TNF inhibitors). Compared with TNF inhibitors, the OR for JAK inhibitors in regards with MACE risk was 0.87 (0.64-1.17, p<0.01). Regarding VTE, a total of 176,951 patients were analysed (41,375 JAK inhibitors users and 135,576 TNF inhibitors users). The OR for VTE for JAK inhibitors compared with TNF inhibitors was 1.28 (0.89-1.84, p<0.01). Conclusion: According to our results, there is no statistically significant difference for MACE or VTE in RA patients who receive either JAK or TNF inhibitors.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Partalidou, S., Patoulias, D., Deuteraiou, K., Avgerou, P., Kitas, G. D., Tzitiridou‐Chatzopoulou, M., & Dimitroulas, T. (2024). Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. Mediterranean Journal of Rheumatology, 35(Suppl 1), 10. https://doi.org/10.31138/mjr.171023.rof

MLA 9

Partalidou, Styliani, et al. “Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.” Mediterranean Journal of Rheumatology, vol. 35, no. Suppl 1, 2024, p. 10. https://doi.org/10.31138/mjr.171023.rof.

Chicago

Partalidou, Styliani, Dimitrios Patoulias, Kleopatra Deuteraiou, Paraskevi Avgerou, George D. Kitas, Maria Tzitiridou‐Chatzopoulou, and Theodoros Dimitroulas. 2024. “Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.” Mediterranean Journal of Rheumatology 35 (Suppl 1): 10. https://doi.org/10.31138/mjr.171023.rof.

Harvard

Partalidou, S. et al. (2024) ‘Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis’, Mediterranean Journal of Rheumatology, 35(Suppl 1), p. 10. doi:10.31138/mjr.171023.rof.

IEEE

S. Partalidou et al., “Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis,” Mediterranean Journal of Rheumatology, vol. 35, no. Suppl 1, p. 10, 2024, doi: 10.31138/mjr.171023.rof.

BibTeX

@article{partalidou2024risk,
  title     = {{Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis}},
  author    = {Partalidou, Styliani and Patoulias, Dimitrios and Deuteraiou, Kleopatra and Avgerou, Paraskevi and Kitas, George D. and Tzitiridou‐Chatzopoulou, Maria and Dimitroulas, Theodoros},
  journal   = {Mediterranean Journal of Rheumatology},
  year      = {2024},
  volume    = {35},
  number    = {Suppl 1},
  pages     = {10},
  doi       = {10.31138/mjr.171023.rof},
  url       = {https://doi.org/10.31138/mjr.171023.rof}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • TNF-alpha inhibitors
  • major adverse cardiovascular events
  • venous thromboembolism
  • deep vein thrombosis
  • pulmonary embolism
  • stroke

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Partalidou, S., Patoulias, D., Deuteraiou, K., Avgerou, P., Kitas, G. D., Tzitiridou‐Chatzopoulou, M., & Dimitroulas, T. (2024). Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. Mediterranean Journal of Rheumatology, 35(Suppl 1), 10. https://doi.org/10.31138/mjr.171023.rof

How many times has this paper been cited?

19 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Mediterranean Journal of Rheumatology: sign in and open the full text from this page.

Who wrote this paper?

Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, Paraskevi Avgerou, George D. Kitas, Maria Tzitiridou‐Chatzopoulou, Theodoros Dimitroulas.

What is the DOI of this paper?

10.31138/mjr.171023.rof, permanently at https://doi.org/10.31138/mjr.171023.rof. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.